| Description |
Author Affiliation: Stewart ZA ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Wilinska ME ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Hartnell S ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Temple RC ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Rayman G ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Stanley KP ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Simmons D ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Law GR ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Scott EM ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Hovorka R ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre (); Murphy HR ( From the Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge (Z.A.S., M.E.W., R.H., H.R.M.), and Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust (S.H., D.S., H.R.M.), Cambridge, the Elsie Bertram Diabetes Centre () |
| Abstract |
BACKGROUND: In patients with type 1 diabetes who are not pregnant, closed-loop (automated) insulin delivery can provide better glycemic control than sensor-augmented pump therapy, but data are lacking on the efficacy, safety, and feasibility of closed-loop therapy during pregnancy. METHODS: We performed an open-label, randomized, crossover study comparing overnight closed-loop therapy with sensor-augmented pump therapy, followed by a continuation phase in which the closed-loop system was used day and night. Sixteen pregnant women with type 1 diabetes completed 4 weeks of closed-loop pump therapy (intervention) and sensor-augmented pump therapy (control) in random order. During the continuation phase, 14 of the participants used the closed-loop system day and night until delivery. The primary outcome was the percentage of time that overnight glucose levels were within the target range (63 to 140 mg per deciliter [3.5 to 7.8 mmol per liter]). RESULTS: The percentage of time that overnight glucose levels were in the target range was higher during closed-loop therapy than during control therapy (74.7% vs. 59.5%; absolute difference, 15.2 percentage points; 95% confidence interval, 6.1 to 24.2; P=0.002). The overnight mean glucose level was lower during closed-loop therapy than during control therapy (119 vs. 133 mg per deciliter [6.6 vs. 7.4 mmol per liter], P=0.009). There were no significant differences between closed-loop and control therapy in the percentage of time in which glucose levels were below the target range (1.3% and 1.9%, respectively; P=0.28), in insulin doses, or in adverse-event rates. During the continuation phase (up to 14.6 additional weeks, including antenatal hospitalizations, labor, and delivery), glucose levels were in the target range 68.7% of the time; the mean glucose level was 126 mg per deciliter (7.0 mmol per liter). No episodes of severe hypoglycemia requiring third-party assistance occurred during either phase. CONCLUSIONS: Overnight closed-loop therapy resulted in better glucose control than sensor-augmented pump therapy in pregnant women with type 1 diabetes. Women receiving day-and-night closed-loop therapy maintained glycemic control during a high proportion of the time in a period that encompassed antenatal hospital admission, labor, and delivery. (Funded by the National Institute for Health Research and others; Current Controlled Trials number, ISRCTN71510001.). |
